Healthy People 2020 Law and Health Policy Project: The Impact of Legal and Policy Strategies on Healthcare Associated Infection Rates
This presentation will discuss progress in reducing healthcare-associated infections (HAI), focusing on Central Line-Associated Bloodstream Infection (CLABSI) rates, and the role of law and policy interventions in those reductions. The data for this project will come from the National Healthcare Safety Network and state and federal level HAI reports. The presentation will discuss the contribution of various sources of incentives for CLABSI reduction, including public reporting of hospital infection rates, NHSN reporting, benchmarking efforts by hospitals, oversight by the Joint Commission and state health agencies, financial incentives, and patient and provider education. A final focus will be on how legal and policy initiatives may impact other HAIs, including surgical site infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia, and implications from the success (incomplete, but meaningful) of CLABSI reduction efforts for progress on other HAIs.
Learning Areas:Public health or related laws, regulations, standards, or guidelines
Evaluate role of law and policy as tools for improving health. Evaluate evidence-based legal and policy approaches from the HP2020 Law and Health Policy report being developed to prevent HAIs and CLABSI. Explain how legal and policy surveillance information can be used in conjunction with health surveillance data to create an evidence base for effective public health interventions. Describe practical information about the use of law and policy to address health factors related to HP2020, in this case, healthcare associated infections.
Keyword(s): Hospitals, Healthy People 2020
Qualified on the content I am responsible for because: Author of Healthy People 2020 Report
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.